- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Winter 2016
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Cerebyx Injection | Pfizer | Fosphenytoin Sodium Injection | Amneal | indicated for the control of generalized tonic-clonic epilepsy and the prevention and treatment of seizures occurring during neurosurgery | 10/6/2016 |
Lamictal ODT | GSK | Lamotrigine Orally Disintegrating Tablets | Dr. Reddy's Labs | treatment of certain types of seizures in epileptic patients | 10/10/2016 |
Merrem | AztraZeneca | Meropenem for Injection | Amneal | treatment for intra-abdominal infections and bacterial meningitis | 10/12/2016 |
Beyaz | Bayer | Rajani | Teva | oral contraceptive | 10/12/2016 |
Abilify | Otsuka | Aripiprazole Tablets | Dr. Reddy's Labs | used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression) | 10/13/2016 |
Vagifem | Novo Nordisk | Yuvafem | Amneal | used after menopause to treat menopausal changes in and around the vagina | 10/18/2016 |
Benicar | Daiichi Sankyo | Olmesartan Medoxomil Tablets | Mylan | indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure | 10/26/2016 |
Benicar HCT | Daiichi Sankyo | Olmesartan Medoxomil / Hydrochlorothiazide Tablets | Mylan | indicated for treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension | 10/26/2016 |
Entocort EC | Perrigo | Budesonide Extended Release Capsules | Mayne Pharma | used as treatment for patients with mild to moderate Crohn's disease | 10/27/2016 |
Benicar | Daiichi Sankyo | Olmesartan Medoxomil Tablets | Sun Pharm | indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure | 10/27/2016 |
Benicar HCT | Daiichi Sankyo | Olmesartan Medoxomil / Hydrochlorothiazide Tablets | Sun Pharm | indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure | 10/27/2016 |
Azor | Daiichi Sankyo | Amlodipine Besylate / Olmesartan Medoxomil Tablets | Sun Pharm | used to treat high blood pressure (hypertension) | 10/27/2016 |
Tribenzor | Daiichi Sankyo | Amlodipine Besylate / Hydrochlorothiazide / Olmesartan Medoxomil Tablets | Sun Pharm | used to treat high blood pressure (hypertension) | 10/27/2016 |
Crestor | AstraZeneca | Rosuvastatin Tablets | Camber Pharms | used to treat high cholesterol and triglyceride levels | 10/31/2016 |
Seroquel XR | AstraZeneca | Quetiapine Fumarate Extended Release (ER) Tablets | Endo | add-on treatment to an antidepressant for patients with major depressive disorder (MDD) who did not have an adequate response to antidepressant therapy; acute depressive episodes in bipolar disorder; acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; long-term treatment of bipolar disorder with lithium or divalproex; and schizophrenia | 11/1/2016 |
Azor | Daiichi Sankyo | Amlodipine Besylate / Olmesartan Medoxomil Tablets | Ajanta | used to treat high blood pressure (hypertension) | 11/2/2016 |
Avodart | GlaxoSmithKline | Dutasteride Capsules | Camber Pharms | used to treat enlarged prostrate | 11/3/2016 |
Levaquin | Ortho-McNeil-Janssen | Levofloxacin Tablets | Camber Pharms | used to treat a variety of bacterial infections | 11/3/2016 |
MS Contin | Purdue Pharma | Morphine Sulfate Extended-Release Tablets | Mayne Pharma | an opioid analgesic for moderate to severe pain management | 11/3/2016 |
Angiomax | The Medicines Company | Bivalirudin for Injection | Fresenius Kabi USA | used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty | 11/7/2016 |
Tribenzor | Daiichi Sankyo | Amlodipine Besylate / Hydrochlorothiazide / Olmesartan Medoxomil Tablets | Teva | indicated for treatment of hypertension, to lower blood pressure | 11/7/2016 |
Azor | Daiichi Sankyo | Amlodipine Besylate / Olmesartan Medoxomil Tablets | Teva | indicated for treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure | 11/7/2016 |
Methergine | Edison Therapeutics | Methylergonovine Maleate Injection | Breckenridge / Ergoject | used for the prevention and control of postpartum hemorrhage | 11/9/2016 |
Evista | Eli Lilly | Raloxifene Hydrochloride Tablets | Dr. Reddy's Labs | prevention and treatment of osteoporosis | 11/11/2016 |
Ditropan XL | Janssen | Oxybutynin Chloride Extended-Release Tablets | Aceto | used in the treatment of overactive bladder | 11/14/2016 |
Activella | Amneal | Amabelz Tablets | Lupin | indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis | 11/15/2016 |
Abilify | Otsuka | Aripiprazole Tablets | Ajanta | used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression) | 11/16/2016 |
Benzamycin Gel | Valeant | Erythromycin / Benzoyl Peroxide Topical Gel | Aceto | used in treatment of acne vulgaris | 11/17/2016 |
Temodar | Merck Sharp & Dohme | Temozolomide Capsules | Mayne Pharma | indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiform concomitantly with radiotherapy and then as maintenance treatment | 11/21/2016 |
Nuvigil | Cephalon | Armodafinil Tablets | Breckenridge / Natco | indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD) | 11/28/2016 |
Nystatin and Triamcinolone Acetonide Cream | Taro Pharms | Nystatin / Triamcinolone Acetonide Cream | Dr. Reddy's Labs | used to treat fungal skin infections | 12/5/2016 |
Tygacil | Pfizer | Tigecycline for Injection | Fresenius Kabi USA | tetracycline class antibacterial indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections; complicated intra-abdominal infections; and community acquired bacterial pneumonia | 12/5/2016 |
CellCept | Hoffman-LaRoche | Mycophenolate Mofetil Hydrochloride for Injection | Endo | indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney, heart, or liver transplants | 12/6/2016 |
Vancocin | ViroPharma | Vancomycin HCI Capsules | ANI Pharms | indicated for treatment of C. difficile-associated diarrhea | 12/10/2016 |
Tamiflu | Hoffman-LaRoche | Oseltamivir Phosphate Capsules | Alvogen | used to treat the flu (influenza) | 12/12/2016 |
Zetia | Merck | Ezetimibe Tablets | Endo / Glenmark | indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia | 12/12/2016 |
Zetia | Merck | Ezetimibe Tablets | Endo / Glenmark | indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol | 12/12/2016 |
EpiPen Auto-Injector | Mylan | Epinephrine Injection | Mylan | emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens | 12/16/2016 |
Vfend | PF Prism | Voriconazole Tablets / Voriconazole Oral Suspension | Lupin | indicated for use in patients 12 years of age and older in the treatment of fungal infections | 12/19/2016 |
Lithobid | Noven Pharms | Lithium Carbonate Extended Release Tablets | ANI Pharms | used in the treatment of manic episodes of Bipolar Disorder, Manic (DSM-IV) | 12/21/2016 |
Kadian | Allergan | Morphine Sulfate Extended Release Tablets | Impax Labs | indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate | 12/22/2016 |
Zovia 1/50E-28 Tablets | Watson | Ethynodiol Diacetate / Ethinyl Estradiol Tablets | Mylan | indicated for use by women to prevent pregnancy | 12/28/2016 |
Cerebyx | Pfizer | Fosphenytoin Sodium Injection | Mylan | treatment of certain types of severe seizures | 12/29/2016 |
Concerta | Janssen | Methylphenidate Hydrochloride Extended-Release Tablets | Mylan | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 12/29/2016 |
GENERICally Speaking Winter 2016
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.